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Although the majority of children with newly diagnosed cancer are expected to be
long-term survivors, cure remains elusive for patients with certain tumor types. For
example, patients with high-risk neuroblastoma, advanced sarcoma, or high-grade
glioma who relapse after initial therapy are rarely cured, and these diseases collectively
account for over half of pediatric cancer deaths.1 Given that further increases or modifications in existing cytotoxic therapies are unlikely to provide substantial benefit, there
is great interest in pursuing alternative approaches for these refractory cancers.
Targeting the immune system as a method for controlling tumor growth is intuitively appealing, as it represents an enabling of the body’s defenses instead of the
usual weakening that is brought about by toxic conventional therapy. There is growing
evidence that the tumor microenvironment and immune effector cells may help control
proliferation of a variety of different pediatric tumors, prompting the investigation of
tumor vaccines or other immunomodulating strategies to eradicate malignant cells,
or at least restrain tumor growth.2–4
The most effective immunotherapy to date for pediatric solid tumors has been the
chimeric monoclonal antibody ch14.18 (dinutuximab; Unituxin®), which targets the
ganglioside GD2 that is ubiquitously present on the surface of neuroblastoma cells.
Use of dinutuximab following autologous stem-cell transplantation improved the
2-year event-free survival for high-risk neuroblastoma patients from 46% to 66%,5
leading to US Food and Drug Administration (FDA) approval of this agent. This
breakthrough study convincingly showed that, in certain contexts, immunotherapy can
indeed improve the outcome for particular pediatric tumors. Given this success, and
the recent expansion of immunotherapies for adult cancers detailed below, attention
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Abstract: While remarkable advances have been made in the treatment of pediatric leukemia
over the past decades, new therapies are needed for children with advanced solid tumors and
high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune
checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown
efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may
also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review
current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the
rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma,
neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial
data available, and suggest potential applications for further study.
Keywords: PD-1, nivolumab, pembrolizumab, pediatric, sarcoma, neuroblastoma, glioma
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is now turning to whether targeting the programmed cell
death-1 (PD-1) pathway will be beneficial for refractory pediatric solid tumors and brain tumors. While responses have
been seen in adult cancers once thought intractable, these
agents have not been efficacious in all clinical scenarios, and
patient selection will be critical for success. In this review,
we discuss the mechanisms and potential biomarkers for
PD-1-targeted therapy, and outline how this may potentially
be applied to pediatric solid tumors.

Overview of PD-1 pathway
In the last three decades, cancer therapy has increasingly
focused on immunotherapy, based in part on observations
that cancer patients may have better outcomes when tumorinfiltrating lymphocytes (TIL) are present.6 The premise is
that these TIL are capable of recognizing and killing tumor
cells, thus leading to prolonged patient survival. Cytotoxic
T-cells are a key mediator of this immune-mediated antitumor
effect, and there is now great interest in understanding how
these cells are not only activated but also regulated.

$

%

As tumor cells die, dendritic cells present tumor-specific
antigens through major histocompatibility complex (MHC)
to T-cells, and provide additional costimulatory signals
through surface receptors like CD28 (Figure 1).7 Once the
T-cell becomes activated, other costimulatory molecules are
expressed, such as 4.1BB, OX40, and CD40L. Activated
T-cells then undergo clonal expansion and migrate to the site
of tumor-related antigens, where they infiltrate the tumor and
kill malignant cells through perforin and granzyme B. Shortly
after activation, mechanisms for turning off the cells also
appear, namely the expression of the checkpoint receptors
CTLA-4 and PD-1. Collectively, these receptors control the
quality, intensity, and duration of the immune response.
Augmenting clonal expansion of these cytotoxic T-cells
has been accomplished with aldesleukin (interleukin 2),
which is FDA approved for the treatment of metastatic renal
cell carcinoma and melanoma.8,9 However, due to the high
toxicity and relatively low response rates of aldesleukin,
focus has shifted from augmenting expansion to prolonging
the activation of cytotoxic T-cells by blocking checkpoint
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Figure 1 Immune response to tumors.
Notes: (A) Dying tumor cells are taken up by antigen-presenting cells (eg, dendritic cells) and presented to T-cells (commonly in the lymph system) where they then
undergo clonal expansion and trafficking into the tumor. (B) Activated cytotoxic T-cells proliferate, participate in generation of inflammatory and toxic cytokines, including
fatal secretion of perforin and granzyme; following chronic stimulation checkpoint receptors on the T-cells are bound by their ligands and the T-cell response is terminated.
Blocking the PD-1 and/or CTLA4 checkpoints with antibodies leads to activation/reactivation of T-cells so they generate an antitumor response.
Abbreviations: MHC, major histocompatibility complex; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.
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signals that can terminate the immune response. Although
checkpoint signals are important to protect against autoimmune disease, they also protect the tumor from immune
attack. The first target for checkpoint inhibition was CTLA-4,
which competes with CD28 to bind the stimulatory molecules B7.1 and B7.2. CTLA-4 expression occurs upon
T-cell activation, and once present CTLA-4 helps terminate
T-cell activity. Ipilimumab is a monoclonal antibody against
CTLA-4, and as such helps remove the brakes on the immune
response and overcome tolerance by prolonging the period
of T-cell activation. Ipilimumab has received FDA approval
for the treatment of metastatic melanoma based on improved
survival when compared to tumor vaccine;10 however, the
overall response rate was only 11%. A pediatric phase I
trial of 33 unselected patients with relapsed solid tumors
treated with ipilimumab identified a maximum-tolerated
dose of 5 mg/kg in patients ,12 years old and 10 mg/kg in
older patients.11 This compares to the FDA-approved dose of
3 mg/kg in adults. Unfortunately, no objective responses were
seen, and focus has turned to second-generation checkpoint
inhibitors targeting PD-1 with the hopes of further improving activity. In adult melanoma patients, pembrolizumab and
nivolumab (PD-1 inhibitors) have proven to be superior to
ipilimumab.12,13
PD-1 is another checkpoint that is important in terminating the response of activated T-cells, and is upregulated by
chronically activated T-cells. PD-1 is expressed on activated
effector T-cells and other TIL such as natural killer cells, and

when activated causes the T-cells to become unresponsive.
This phenotype of PD-1+ T-cells that is no longer cytotoxic
is called T-cell exhaustion. Of note, mice deficient in PD-1
develop autoimmune diseases from unchecked immune
activation, and blocking this pathway in PD-1-proficient
mice with chronic viral infections restores antiviral immunity
and reverses T-cell exhaustion.14 PD-1 signaling is induced
following binding to either of its two ligands (PD-L1 or
PD-L2), of which PD-L1 appears to be the more important
in regulating T-cell antitumor function. PD-L1 is expressed
in a variety of different tumors, and in dendritic cells, macrophages, and T-cells. Upregulation of PD-L1 expression
by tumors is driven by inflammation when cytokines such
as interferon gamma are expressed. Additionally, there is
also a link between hypoxia, which can lead to infiltration
of tumor-associated macrophages that express PD-L1. These
immune-regulatory signals appear to be a mechanism tumors
utilize to escape immune surveillance. Logically, it follows
that tumors that express PD-L1 or contain macrophages
that express PD-L1 might respond best to a PD-1 or PD-L1
inhibitor.15 This concept is depicted in Figure 2.
There are currently three FDA-approved antibodies
targeting either PD-1 (nivolumab, pembrolizumab) or
PD-L1 (aletuzumab), with several others in clinical trials.
A summary is provided in Table 1. To date, there has been
no published comparison of efficacy in patients treated with
antibodies within a class (eg, nivolumab vs pembrolizumab),
or between classes (PD-1 vs PD-L1). The toxicities of these
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Figure 2 Escaping immune surveillance.
Notes: T-cells in the immune system recognize and eliminate immunogenic transformed cells. However, some cells do not express enough neoantigens to be recognized by
the immune system, while others express ligands for checkpoint receptors on T-cells to terminate the immune response.
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Table 1 Checkpoint inhibitors available in the USA and select inhibitors in advanced studies
Drug

Target

Indication

Stage of development

Ipilimumab
Tremulimumab

CTLA4
CTLA4

Pembrolizumab

PD-1

FDA approved
Phase III – NCT02369874
Phase III – NCT01843374
Phase III – NCT02542293
FDA approved

Nivolumab

PD-1

Pidilizumab

PD-1

PDR001
Atezolizumab

PD-1
PD-L1

Durvalumab

PD-L1

Avelumab

PD-L1

Melanoma
Head and neck
Mesothelioma
Non-small-cell lung cancer
Non-small-cell lung cancer
Melanoma
Head and neck cancer
Non-small-cell lung cancer
Melanoma
Renal cell cancer
Head and neck cancer
Hodgkin lymphoma
Diffuse large B-cell lymphoma
Multiple myeloma
Neuroendocrine tumors
Non-small-cell lung cancer
Bladder cancer
Head and neck cancer
Non-small-cell lung cancer
Non-small-cell lung cancer
Breast cancer
Ovarian cancer

Phase II – NCT02530125
Phase I/II – NCT02077959
Phase II – NCT02955069
FDA approved
Phase III – NCT02369874
Phase III – NCT02453282
Phase III – NCT02576574
Phase III – NCT02926196
Phase III – NCT02580058

Abbreviations: FDA, Food and Drug Administration; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.

compounds are nearly similar, with autoimmune adverse
events being most common and concerning.16 Historically,
immunotherapy was thought to only be efficacious in the
setting of minimal residual disease;17 however, PD-1-targeted
antibodies have routinely produced responses in patients
with bulky disease.

Putative biomarkers and mechanisms of
resistance for PD-1-targeted therapy
At present, there is no single biomarker that accurately predicts response to anti-PD-1 therapy. Based on the current
understanding of the immune system’s antitumor response,
there are several key elements that can explain how tumors
escape immune surveillance and grow. Tumors that are
not immunogenic will not be recognized by the immune
system. Immunogenic tumors can avoid immune surveillance by preventing inflammation and lymphocyte penetration into the tumor, or they can avoid immune surveillance
by terminating the immune response through expressed
checkpoint ligands.
Intuitively, tumors that have escaped immune surveillance and express PD-L1 on the cell surface should benefit
from either anti-PD-1 or anti-PD-L1 therapy. However,
clinical trial experience shows that this is not always the
case.18 Key areas of investigation include how expression
of PD-L1 is assessed, what threshold is linked to clinical
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benefit from these agents, and whether PD-L1 expression is
required for therapeutic success. As seen in Table 2, PD-L1
is most commonly assessed by immunohistochemistry
(IHC), although a variety of different antibodies, different
tissues (fresh, frozen, paraffin embedded, primary vs metastatic), and different thresholds for positivity have been used
(reviewed in Hutarew).19 Despite these limitations, most
trials involving lung cancer and melanoma patients show
a general association between outcome and PD-L1 expression, although it is not necessarily required for therapeutic
benefit.18 In contrast, PD-L1 expression in urothelial cancer
or renal cell cancer seems even less predictive of response to
nivolumab20,21 or pembrolizumab22, as some patients clearly
benefit despite little or no expression. These results suggest
that the utility of PD-L1 as a biomarker is limited and may
not be broadly applicable across all tumor types.
PD-L1 expression is induced by inflammatory cytokines
such as interferon gamma, and the expression of this cytokine
may mark the mechanism the tumor has utilized to escape
immune surveillance and consequently be a biomarker for
PD-1 inhibitor activity. For example, in a preliminary report
describing the treatment of patients with non-small-cell lung
cancer with the anti-PD-L1 antibody durvalumab, patients
whose tumors coexpressed interferon gamma and PD-L1
had improved survival (hazard ratio [HR] 0.4, P=0.016)
compared with those expressing PD-L1 alone (HR 0.64,

OncoTargets and Therapy 2017:10

Dovepress

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

Table 2 Review of select biomarker studies and their ability to enrich responding patient populations
Biomarker

Drug

Disease/
setting

Cutoff

Outcome

Comment

Tumor PD-L1

Pembrolizumab59

NSCLC
Mostly
second line

1%–24%
25%–49%

OS – 10 mo
OS – 10 mo

Automated IHC assay with antibody 22C3
Food and Drug Administration-approved test –
positive = TPS 50%+

50%–74%
75%+
,5%

OS – 16 mo
OS – 17 mo
OS – 10 mo

5%+

OS – 19 mo

,1%
.1%
.5%
.50%
,5%
.5%
,1%
1%+

OS – 13 mo
OS – 16 mo
OS – 16 mo
OS – 21 mo
PFS – 5 mo
PFS – 22 mo
PFS – 3 mo
PFS – 12 mo

SP142 assay

Positive predictive value

40%

Interferon gamma genes: CXCL9, CXCL10

Negative predictive value
Teff/INF high

IDO1, INF gamma, HLA-DRA, and STAT1
Teff/INF gamma gene signature
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Nivolumab60

Atezolizumab61

Nivolumab62
Pembrolizumab63

Inflammatory
gene
Signature

Pembrolizumab64

Atezolizumab65

Mutational
burden

Pembrolizumab66

Pembrolizumab66

Pembrolizumab24

Angiopoietin 2

PD-1 inhibitor25

NSCLC
second line
(nonsquamous
histology)
NSCLC
Second line

Melanoma
First line
Melanoma
Prior
treatment
Head and neck
cancer
Second line
NSCLC
Second line

Teff/INF low

95%
OS – NR median
follow-up ~15 mo
OS ~10 mo

NSCLC

High (above median)

ORR – 59%

Prior
treatment
NSCLC
Prior
treatment
Colorectal
cancer
Second line
Melanoma

Low (below median)

ORR – 12

High (above median)
Low (below median)

PFS – 14.5 mo
PFS – 4.1 mo

Mismatch repair deficient

ORR – 40%

Mismatch repair proficient
Low baseline with small
increase w/tx
High baseline with high
increase w/tx

ORR – 0%
OS =34.6 mo

Second line

OS =7.9 mo

IHC assay with antibody 28-8

IHC assay with antibody 28-8
From pooled analysis
IHC assay with antibody 22C3

Determined by gene expression of CD8A
GZMA, GZMB, INF gamma, EOMES, CXCL9
CXCL10 and TBX21
Nonsynonymous
Exom sequencing with 9049 nonsynonymous,
coding point mutations considered
Total exonic mutations

Microsatellite instability analysis using an assay
from Promega
Serum-based assay
Monitored serially – association with vascular
endothelial growth factor

Abbreviations: INF, interferon; IHC, immunohistochemistry; mo, months; NSCLC, non-small-cell lung cancer; OS, overall survival; PD-1, programmed cell death-1; PD-L1,
programmed death-ligand 1; PFS, progression-free survival.

P=0.18).23 These findings suggest that some type of panel of
biomarkers may be most efficacious for patient selection.
Another putative biomarker for response to anti-PD-1
therapy is the total mutational burden, with studies showing
improved response rates in patients with .100 mutations
in tumor tissue.18 Somatic mutations have the potential
to encode “non-self” immunogenic antigens (also called
neoantigens), which may make the tumor more visible to
the immune system. Mutations may be induced by exposure,
such as sunlight or cigarette smoke, and perhaps this may be

OncoTargets and Therapy 2017:10

one reason why PD-1 agents have been successful in melanoma and lung cancer. Alternatively, mutations also may be
dramatically increased in tumors demonstrating mismatch
repair (MMR) deficiency, and this can result in microsatellite instability (MSI) and sensitivity to PD-1 inhibition. For
example, patients treated with pembrolizumab for colon
cancer showed response rates as high as 40% in patients
whose tumors showed MMR deficiency, compared with
0% in MMR-proficient tumors.24 Whole-exome sequencing
demonstrated a mean of 1,782 mutations per tumor in the
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MMR-deficient cohort, compared to 73 in the proficient
group. Assessing for mutational burden and MSI can now be
done by commercial assays, and may be another potentially
important factor to consider regarding patient selection.
Finally, there is some recent information suggesting that
angiopoietin-2 (Ang2) may also be a biomarker for PD-1targeted therapy, and importantly one that can be assessed
by peripheral blood at various time points. Ang2 is a critical
regulator of tumor-associated blood vessel maturation, and
is involved with the recruitment of monocytes/macrophages
into the tumor microenvironment and induction of PD-L1
expression in M2-polarized macrophages. Wu et al found
that for 43 melanoma patients treated with PD-1 blockade, those with high circulating levels of Ang2 (defined
as .3,175 pg/mL) or rising levels during treatment had
reduced overall survival,25 suggesting that Ang2 may mediate resistance to checkpoint inhibitors, and could be used to
select and follow patients. Although pediatric data are limited, one study of 35 various pediatric solid tumor or brain
tumor patients showed that the median circulating Ang2
level at diagnosis would be considered low at 2,482 pg/mL,
suggesting potential sensitivity to PD-1 inhibition according
to this parameter.26 A list of biomarkers used in key clinical
trials is provided in Table 2.
There are several proposed mechanisms of resistance to
PD-1 blockade, and include interruptions of any step along
the pathway of T-cell cytotoxicity. Some tumors such as
prostate cancer have very little PD-L1 expression despite
the presence of TIL, and so may be resistant for this reason.27 Mutations in tumor can account for downregulation of
MHC and decreased immunogenicity,28 or altered dendritic
cell migration.29 In addition, involvement of other PD-1independent pathways may help tumor cells evade T-cell
destruction. Some tumor cells are induced by interferon
gamma to express indoleamine 2,3-dioxygenase, which can
render experimental models of melanoma resistant to PD-1
blockade.30 Other complex mechanisms such as extreme
T-cell exhaustion or impaired development of effective
T-cell memory may also contribute to resistance (reviewed
in O’Donnell et al).31

Preclinical testing in pediatric cancers
In considering whether PD-1 targeting would be appropriate
for pediatric cancers, a key issue is whether potential biomarkers suggested by adult studies are present in childhood
tumors as well. Although limited, there is a growing body of
evidence about PD-L1 expression, mutational burden, and
MSI in important childhood cancers such as bone and soft
tissue sarcoma, neuroblastoma, and high-grade glioma.
2102
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Pediatric sarcoma
In two of the larger studies to date of osteosarcoma, IHC
analysis showed PD-L1 expression in 25%–47% of primary
tumor samples, and tumors expressing PD-L1 were significantly more likely to have infiltrating immune cells, which
often expressed PD-1.32,33 Importantly, PD-L1 expression
correlated with worse event-free survival, and these findings
are consistent with the concept that PD-L1 in tumor cells may
interact with PD-1-expressing cells in the microenvironment
to help evade immune rejection by the host. Interestingly,
PD-L1 expression has been reported to be more common
in metastatic lesions than in primary tumors,34,35 which is
relevant considering that metastases are more likely than
primary tumors to cause death in this disease. Further, osteosarcoma has a greater inherent genomic instability and higher
mutational burden than many other pediatric solid tumors,36
which may also predispose to benefit from PD-1-targeted
therapy. Finally, use of the immune adjuvant mifamurtide has
previously shown benefit in osteosarcoma37 and is approved
by the European Medicines Agency, further demonstrating
the potential role of immunotherapy for this disease.
PD-L1 expression has been less well studied in Ewing
sarcoma, another important pediatric sarcoma that may originate either in bone or soft tissue. One study demonstrated
expression in 8 (57%) of 14 primary bone tumor samples,32
while 8 (38%) of 21 soft tissue primaries have reported
PD-L1 expression in other studies.38,39 For rhabdomyosarcoma, the most common pediatric soft tissue sarcoma, data
are limited but Chowdhury et al have reported expression in
13 (86%) of 15 alveolar rhabdomyosarcoma and 8 (50%) of
16 embryonal rhabdomyosarcoma patient samples.32 More
robust analysis of the tumor microenvironment is not yet
available, although infiltrating PD-1 CD8 lymphocytes are
present in a subset of these tumors.

Neuroblastoma
Neuroblastoma is the most common extracranial solid
tumor in children, and high-risk disease accounts for up
to 15% of pediatric cancer deaths. An early study did not
identify PD-L1 expression in any of the 18 tested samples
from neuroblastoma patients.40 In contrast, Chowdhury et al
reported PD-L1 surface expression in 31 (72%) of 43 patient
tumor samples,32 with lower survival in patients expressing PD-L1. Dondero et al confirmed that PD-1 expression
is present in lymphocytes obtained from metastatic bone
marrow samples, and that PD-L1 expression in tumor cells
is inducible with interferon gamma.41 Interestingly, the production of cytokines such as interferon is particularly high
in patients following treatment with the recently approved
OncoTargets and Therapy 2017:10
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monoclonal antibody dinutuximab, suggesting potential
benefit for combination therapy.
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High-grade glioma
PD-L1 expression has been identified in 6 (30%) of 20
pediatric high-grade glioma samples,42 and larger studies in
adults showed expression in 68% of 62 glioblastoma samples,
with a strong trend for worse outcome in these patients.43
In addition, a subset of pediatric high-grade glioma tumors
has evidence of MSI, which reflects the increased mutational status of the tumor and the potential greater number
of neoantigens that could induce a host immune response.
Viana-Pereira et al have reported MSI to be present in 14
(19%) of 71 high-grade glioma samples, significantly higher
than that seen with adult tumors.44 While some of those
patients may have had the rare congenital MMR deficiency
syndrome (MMRDS, previously called Turcot syndrome),45
MSI may also arise independently outside of this defined
cancer predisposition. The potential benefit for using antiPD-1 antibodies to treat these hypermutated tumors was
shown by Bouffet et al, who reported sustained responses in
two siblings with pediatric glioblastoma and MMRDS who
were treated with single-agent nivolumab.46 Taken together,
these findings support further investigation of PD-1-targeted
drugs for this disease.

Completed and upcoming clinical trials
with PD-1 agents to treat pediatric
cancers
To date, there have been only a few reports of treatment
of pediatric cancer patients with agents targeting the PD-1
pathway. Apart from the glioma patients with MMR deficiency treated with pembrolizumab as above,46 all other
reports involve genetically unselected patients. Blumenthal
et al retrospectively described outcomes in 22 patients with
recurrent primary brain tumors treated with pembrolizumab,
of whom five were children with pontine glioma (2), glioblastoma (1), atypical teratoid/rhabdoid tumor (1), and

medulloblastoma (1).47 These children were ages 3–7 years,
and received an adjusted flat dose of 50 mg every 3 weeks for
a median of four infusions (range 2–10). Disappointingly, no
responses were seen in either pediatric or adult patients.
Although preclinical data would suggest that osteosarcoma would be sensitive to agents targeting PD-1, this
has not been the case in the limited data available to date.
For example, in the SARC028 multi-institutional phase II
trial of pembrolizumab, only one of 19 patients with recurrent osteosarcoma had an objective imaging response.48 In
addition, no responses were seen in 13 patients treated with
recurrent Ewing sarcoma, although there has been one anecdotal case report of a heavily pretreated patient with relapsed
disease who had a sustained response to pembrolizumab.49
Interestingly, the SARC028 study did show activity for a
subset of adult soft tissue sarcoma, namely undifferentiated
pleomorphic sarcoma, in which four of 10 patients experienced a partial response. This sarcoma histiotype is somewhat
heterogeneous, and it is not known whether PD-1 agents will
have similar efficacy in the soft tissue sarcoma subtypes more
commonly seen in pediatrics such as rhabdomyosarcoma.
Table 3 lists several key ongoing clinical trials in
pediatric patients, which are expected to better establish
the potential role of anti-PD-1 antibodies and hopefully
identify biomarkers that can be used for patient selection.
The Children’s Oncology Group is performing an important
phase I/II study that will determine both the recommended
phase II doses of single-agent nivolumab and the combination of nivolumab with the CTLA-4 inhibitor ipilimumab in
patients with unselected recurrent solid tumors or lymphoma
(ClinicalTrials.gov identifier NCT02304458). In the phase II
expansion portion of the study, activity of nivolumab will
be assessed in at least 10 patients in each of the following
cohorts: neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, non-Hodgkin
lymphoma, and melanoma. If sufficient activity is not seen
in a cohort treated with nivolumab, then the activity of the
combination of nivolumab and ipilimumab will be assessed

Table 3 Ongoing trials of agents targeting the PD-1 or PD-L1 pathway for treatment of pediatric cancer
ClinicalTrials.gov
identifier

Population

Agent

Other drugs

Design

Sponsor/comments

NCT02304458
NCT02332668

Relapsed solid tumors
Melanoma, PD-L1 positive
solid tumors or lymphoma
Recurrent high-grade glioma
Recurrent solid tumors
Recurrent solid tumors
Recurrent osteosarcoma

Nivolumab
Pembrolizumab

+/−Ipilimumab
–

Phase I/II
Phase I/II

COG
35 institutions

Pembrolizumab
Nivolumab
Atezolizumab
Avelumab

–
Cyclophosphamide
–
–

Phase I/II
Basket trial
Phase I/II
Phase II

PBTC
European study
Hoffmann-LaRoche
St Jude

NCT02359565
NCT02813135
NCT02541604
NCT03006848

Abbreviations: COG, Children’s Oncology Group; PBTC, Pediatric Brain Tumor Consortium; PD-L1, programmed death-ligand 1; PD-1, programmed cell death-1.
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for that tumor type. This expansive trial includes many correlative studies and should help better define the role of PD-1
inhibition in treating pediatric tumors.
Other ongoing studies include a Pediatric Brain Tumor
Consortium phase I/II study in which pembrolizumab is
being evaluated for treatment of recurrent high-grade glioma
or other hypermutated brain tumors (NCT02359565). Pembrolizumab is also being studied in a pediatric phase I/II
trial as single-agent treatment for recurrent melanoma or
PD-L1-positive tumors (NCT02332668). In addition, antiPD-1 antibodies are also being included in so-called “basket
trials” for recurrent pediatric solid tumors, in which patients
are stratified based on molecular characteristics of the
tumor rather than the histiotype (NCT02813135). In regard
to PD-L1 antibodies, a phase I/II study of atezolizumab is
now open for patients ,30 years with recurrent solid tumors
(NCT02541604), and a phase II study of avelumab is open
for patients with recurrent osteosarcoma (NCT03006848).

Safety and response considerations
As opposed to the myelosuppression usually seen with
conventional chemotherapy, the toxicity of anti-PD-1 antibodies has often been immune-related such as pneumonitis,
colitis, hepatitis, hypophysitis, and thyroiditis.16 In general, the occurrence of these toxicities has correlated with
antitumor effects, consistent with the mechanism of action
of these agents. In the limited number of pediatric patients
studied to date, the severity and scope of adverse events
seem similar to adults. The development of pneumonitis and
pleural effusions is of particular concern in pediatric sarcoma
patients, who commonly have bulky lung or pleural metastases that may be associated with effusions. Such patients
being treated with anti-PD-1 antibodies should be monitored
carefully, and be considered for drainage or other medical
management that could include steroids.50
Another characteristic of PD-1-targeted therapy is the
potential for the temporary increase in size of lesions as a
consequence of therapy-related inflammation. This effect is
termed pseudoprogression, and has led to the development
of a modified response assessment system called immunerelated response criteria that are now used in trials of these
agents.51 This revised system allows for more interval growth
of tumor to occur before the determination of progressive
disease is made, based on past observations of patients going
on to have prolonged disease stability despite some initial
growth of tumor. The concept of tumor pseudoprogression
may have the greatest clinical implications in the treatment
of brain tumors, as at least one death has now been reported
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in a pediatric patient with recurrent glioblastoma who was
treated with nivolumab and developed fatal cerebral edema
despite operative intervention.52

Combination therapies
Given the common tendency of cancers to develop resistance
to monotherapies, it is likely that some patients may benefit
only when PD-1 agents are combined with other drugs that
may be synergistic. The only FDA-approved combination is
nivolumab together with the CTLA-4 inhibitor ipilimumab
for the treatment of metastatic melanoma. While this intuitively appealing strategy of double checkpoint inhibition
increases the response rate and overall survival, the rate
of grade 3–4 toxicity is also increased when compared to
nivolumab alone,53 emphasizing that toxicity considerations
will be important when planning combination therapies.
Some conventional chemotherapy drugs such as cyclophosphamide, platinum analogs, and taxanes can elicit
immunogenicity by recruiting immune cells to the microenvironment, stimulating natural killer-dependent antitumor
immunity and T-cell responses, and disrupting immune
suppressor mechanisms by depleting regulatory T-cells and
myeloid-derived suppressor cells.54 These immunomodulatory effects may be optimized by using lower or more protracted dosing,55 and this strategy is being utilized in an
ongoing pediatric study combining pembrolizumab with
low-dose oral cyclophosphamide (NCT02813135).
The ability of radiotherapy to induce immune responses
is only now beginning to be understood. Preclinical studies
suggest that the combination of a PD-1 antibody with radiation can be synergistic,56 and combination phase III studies
are now underway for glioblastoma (NCT02617589) and
lung cancer (NCT027768558). If this strategy is successful in
adults, it is likely that pediatric trials combining radiotherapy
and anti-PD-1 antibodies will soon follow. Other possible
combinations include targeted agents such as dabrafenib
or trametinib together with anti-PD-1 therapy,57 or even
tumor vaccines58 or oncolytic viruses such as tailmogene
laherparepvecm, which produces GM-CSF and is being
evaluated together with pembrolizumab in a phase III trial
for melanoma patients (NCT02263508).

Conclusions and future directions
The use of PD-1-targeted agents has revolutionized the
treatment of certain adult cancers, generating excitement in
part because some of the most responsive tumors have been
previously refractory to conventional therapies. Still emerging is the identification of a reliable biomarker or panel of
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characteristics that can allow appropriate patient selection.
Available information to date suggests that PD-L1 expression on tumor cells, a strong lymphocytic presence in the
tumor microenvironment, and an increased mutational
burden are important but not yet definitive markers that
suggest efficacy. These features are variably present in some
high-risk pediatric tumors, and support further investigation
of PD-1-targeted therapy. However, data from adult studies
clearly show that the presence or absence of these putative
biomarkers does not guarantee the success or failure of this
therapeutic strategy. Although off-label use is tempting for
patients with multiply recurrent tumors, caution should be
taken in light of the still unproven benefit of these agents
for pediatric cancers, and the potential for organ toxicity
related to immune effects. Trials are underway, which will
better define the role these drugs may play for treating
pediatric cancers, either as single agents or in combination
with chemotherapy, radiation, or other molecularly targeted
or biologic therapies.
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